Astraveus advanced validation of its Lakhesys microfluidic cell therapy platform this week, highlighting new prototype data and external expert feedback. The company hosted representatives from Institut Paoli-Calmettes at its Paris facility for evaluation runs comparing Lakhesys against an unnamed industry benchmark in lentiviral-based CAR-T manufacturing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Early results indicate Lakhesys delivered roughly 2.5x higher transduction efficiency than the benchmark while using low-volume lentiviral delivery and no additional reagents. According to qualitative feedback cited by Astraveus, cell therapy manufacturing leaders viewed the platform as a meaningful innovation for CAR-T and decentralized, point-of-care production.
These evaluations were conducted on a new two-unit functional prototype, signaling progress along Astraveus’ product development roadmap toward more mature hardware suitable for external testing. The company is positioning Lakhesys within broader industry trends toward automation, process intensification, and point-of-care manufacturing for advanced therapies.
Astraveus is also expanding its evaluation programs by inviting additional clinical and manufacturing users to participate in co-development efforts. This strategy aims to gather real-world workflow, usability, and performance data early in the lifecycle, helping to reduce technical and adoption risks in a highly regulated manufacturing environment.
If Lakhesys’ efficiency gains are confirmed at scale and in diverse settings, the platform could enable lower reagent costs, improved yields, and more competitive economics for cell therapy manufacturing. Such outcomes would enhance Astraveus’ strategic value as a tools provider to biopharma and cancer centers seeking to internalize or scale cell therapy production.
The company’s focus on microfluidics, decentralized manufacturing, and close collaboration with hospitals and therapy developers may support future commercialization and partnership discussions. Overall, the week underscored Astraveus’ continued technical progress and ecosystem engagement as it works to make cell therapies more accessible and economically viable.